Publication of a new article by our CSO in the scientific journal Current Opinion in Oncology
We are delighted to announce of the publication by our CSO Joël Plumas of a new review article in scientific journal Current Opinion in Oncology and intitled "Harnessing dendritic cells for innovative therapeutic cancer vaccines"!
Purpose of review
The clinical activity of new immunotherapies in cancer, such as anti-Programmed cell death 1 (PD-1)/ Programmed death-ligand 1, has revealed the importance of the patient’s immune system in controlling tumor development. As in infectious diseases, dendritic cells (DCs) are critical for inducing immune responses in cancer. Unfortunately, autologous DC-based vaccines have not yet demonstrated their clinical
benefit. Here, we review recent research using allogeneic DCs as alternatives to autologous DCs to develop innovative therapeutic cancer vaccines.
Recent findings
A novel approach using an allogeneic plasmacytoid dendritic cell (PDC) line as an antigen presentation platform showed great potency when used to prime and expand antitumor-specific CD8þ T cells in vitro and in vivo in a humanized mouse model. This PDC platform, named PDCvac, was first evaluated in the treatment of melanoma with encouraging results and is currently being evaluated in the treatment of lung cancer in combination with anti-PD-1 immunotherapy.
Summary
Therapeutic cancer vaccines are of particular interest because they aim to help patients, to mount effective antitumor responses, especially those who insufficiently respond to immune checkpoint inhibitors. The use of an allogeneic plasmacytoid DC-based platform such as PDC*vac could greatly potentiate the efficacy of these new immunotherapies.
Please find enclosed the full article in PDF version below:
